Stem-Cell Transplantation
Allogeneic transplantation therapeutic option for myeloproliferative diseases
Published in Cancer Weekly, July 6th, 2004
"The role of allogeneic transplantation for myeloproliferative diseases other than chronic myeloid leukemia is not well established," wrote researchers at M.D Anderson Cancer Center.
"In all," said P. Mittal and colleagues, "20 patients with a median age of 51 years underwent allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis (n=5), chronic myelomonocytic leukemia (CMML) (n=8) and Philadelphia (Ph) chromosome-negative/BCR-ABL-negative chronic myeloid leukemia (CML) (n=7) in our institution. Patients who developed acute leukemia prior to HSCT...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2004-07-06)
More Articles from Cancer Weekly
- Antioxidants
Ascorbic acid makes cancer cells insensitive to chemotherapy - Chemotherapy
Cell density affects the cytotoxicity of daunorubicin and cytosine arabinoside - Hematology
Hematopoietic growth factors manage the effects of non-Hodgkin lymphoma therapy - Oncology
Thrombospondin 1 bears fragments that counteract its antiangiogenic potential - Radiotherapy
HIM-prostate brachytherapy performs well in the community setting - Abdominal Surgery
Surgical interdisciplinarity is needed for abdominal surgery - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
